DMAA updates CFO equity to 175k shares, sets CEO compensation terms, both tied to definitive deal

Drugs Made In America Acquisition Corp.

CFO Saleem Elmasri's share grant increased from 100k to 175k ordinary shares, earned upon signing a definitive agreement and issued at closing of initial business combination.
CEO Roger Bendelac receives 250k ordinary shares under same vesting trigger; monthly cash comp of $4,500 with up to $2,000 deferrable based on cash flow.
Monthly CFO fee unchanged at $3,500; unpaid amounts accrue as binding obligations; shares replace prior unissued 100k.
Compensation structures signal progress toward a business combination, though no definitive agreement announced as of April 28, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.